Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: Results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial

Journal

Related Articles

See more

Details 詳細情報について

  • CRID
    1370004968582122889
  • Data Source
    • Crossref
Back to top